SQUAWK/NEWS
Account
Theme
Account
Menu
Live News MNA FLASH L impact

Gilead Agrees to Pay $1.275 Billion Upfront for Oral Peptide Program

Gilead’s deal for a Phase 1 oral peptide program highlights developers including Entera, which is approaching Phase 3 in osteoporosis.

ENTXGILD

Related stories